Faculty of Pharmacy, University Teknologi MARA (UiTM), 42300 Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia.
Collaborative Drug Discovery Research (CDDR) Group, Pharmaceutical and Life Sciences Community of Research, Universiti Teknologi MARA (UiTM), 40450 Shah Alam, Selangor Darul Ehsan, Malaysia.
J Neurosci Res. 2017 Oct;95(10):2005-2024. doi: 10.1002/jnr.24048. Epub 2017 Mar 16.
The rapid increase in the older population has made age-related diseases like Alzheimer's disease (AD) a global concern. Given that there is still no cure for this neurodegenerative disease, the drastic growth in the number of susceptible individuals represents a major emerging threat to public health. The poor understanding of the mechanisms underlying AD is deemed the greatest stumbling block against progress in definitive diagnosis and management of this disease. There is a dire need for biomarkers that can facilitate early diagnosis, classification, prognosis, and treatment response. Efforts have been directed toward discovery of reliable and distinctive AD biomarkers but with very little success. With the recent emergence of high-throughput technology that is able to collect and catalogue vast datasets of small metabolites, metabolomics offers hope for a better understanding of AD and subsequent identification of biomarkers. This review article highlights the potential of using multiple metabolomics platforms as useful means in uncovering AD biomarkers from body fluids. © 2017 Wiley Periodicals, Inc.
人口老龄化的迅速增加使得与年龄相关的疾病（如阿尔茨海默病）成为全球关注的焦点。鉴于这种神经退行性疾病仍然无法治愈，易感人群数量的急剧增长代表了对公共健康的主要新威胁。对阿尔茨海默病发病机制的了解不足被认为是在对这种疾病进行明确诊断和管理方面取得进展的最大绊脚石。非常需要能够促进早期诊断、分类、预后和治疗反应的生物标志物。已经有人努力寻找可靠且独特的阿尔茨海默病生物标志物，但收效甚微。随着高通量技术的出现，该技术能够收集和编目大量的小分子代谢物数据集，代谢组学为更好地了解阿尔茨海默病并随后确定生物标志物提供了希望。本文综述了使用多种代谢组学平台作为从体液中发现阿尔茨海默病生物标志物的有用手段的潜力。 © 2017 威利父子公司
